NanobiotixCompany Details

Get alertedif Nanobiotix gets funded!
Country:
City:
France
Paris
Industry:Biotechnology
Detailed industries:biotech
Company description

Nanobiotix is dedicated to finding new treatments for cancer based on the combined application of nanotechnologies and biotechnologies. Nanobiotix currently develops NanoBiodrugs which are precisely targeting abnormal cells and destroying them through the controlled generation of physical or chemical reactions triggered by external activation. Nanobiodrugs are composed of two parts:an inorganic core which, through activation(for example the application of an external field such as MRI) will cause the destruction of the targeted cells anda targeting molecule which will guide the ...Nanobiodrug to the target. This unique mode of action explains the accuracy of the therapeutic activity and the expected excellent tolerance. Furthermore, because the activity is triggered externally, this implies a total control of the activity of the NanoBioDrugs. So far Nanobiotix has demonstrated both in vitro and in vivo both the accuracy of the targeting and the tolerance of the NanoBiodrugs currently under development. In vitro experiments have validated the concept of cell destruction through external activation and the absolute control of this process, with the emergence of an activation time-cell destruction function. Promising large animal studies on various cancer models and different compounds are currently under way. Historically, Nanobiotix has developed a very tight partnership with the State University of New York (SUNY) at Buffalo, NY where its founders initiated the development of this innovative technology within the Institute for Lasers, Photonics and Biophotonics. This has allowed Nanobiotix to capitalize on the extensive knowledge on nanoparticles developed in the SUNY in Buffalo, NY and to benefit from its state-of-the-art facilities. Currently Nanobiotix holds the rights and patents on different nanobiodrug families (MRI, Laser, and Ultra sound activated) and is actively broadening its portfolio of patents which will allow the development of different types of particles, activated in different ways, to explore new indications in the field of cancer. With the development of numerous new compounds on this model, Nanobiotix is becoming a leader in the field of cancer treatments relying upon both nanotechnology and biotechnology. MoreLess

 

Funding history

DateDeal sizeInvestors 
October 31st, 2017$35,753,400-View Deal
April 7th, 2017$33,237,420-View Deal
March 15th, 2016$28,205,460-View Deal
July 6th, 2013$11,917,800-View Deal
October 24th, 2012$18,803,640-View Deal
Create alert
Want to know when Nanobiotix gets funded?
Key people
Kader BoussahaCFO & COO
Laurent LevyCEO
Please note that all data is automatically extracted and errors can occur.
The WhoGotFunded team has not necessarily reviewed the information in this page and has not determined if it is accurate and complete.
Inaccurate Data? Help us improve WhoGotFunded: post a comment!